Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03790488 · ClinicalTrials.gov registry record · Phase 1
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
A Phase 1 study, sponsored by Jounce Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03790488: Completed Phase 1 study, sponsored by Jounce Therapeutics.
NCT03790488 is a Phase 1 study that has completed, run by Jounce Therapeutics. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03790488, a Phase 1 study, has completed, sponsored by Jounce Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult subjects with advanced refractory solid tumor malignancies, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
Interventions
- DRUG JTX-4014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03790488
The ClinicalTrials.gov registry entry for NCT03790488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jounce Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JTX-4014 is the first listed.
NCT03790488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03790488 about?
NCT03790488 is a clinical study titled "Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies". JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult subjects with advanced refractory solid tumor malignancies, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
What is the current status of trial NCT03790488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-12-06. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT03790488?
The interventions under investigation include: JTX-4014 (DRUG).
Who is sponsoring clinical trial NCT03790488?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.